Oncology

Why are we still treating cancer prevention as adjunctive care?

Adopting a healthy lifestyle correlates with reduced risk for 13 distinct cancer types, highlighting the role of modifiable factors in oncology.

Chemo hair loss: Why some patients feel it more deeply

Distress from chemotherapy-induced hair loss is disproportionately higher among younger women and Black women, highlighting an unmet need for targeted support.

Olaparib: Why HRD in breast and ovarian cancer goes beyond BRCA

Olaparib demonstrated activity in HR-deficient metastatic triple-negative breast cancer and platinum-sensitive relapsed ovarian cancer without germline BRCA1/2 mutations.

Multicancer tests: Can we screen without knowing the outcome?

An FDA panel recently reviewed multicancer early detection tests, highlighting significant data gaps regarding their clinical utility and impact on patient outcomes.

Salivary gland cancer: Is HER2-low the new HER2-positive?

Trastuzumab rezetecan demonstrated antitumor activity in advanced salivary gland carcinoma, particularly in HER2-high disease, with a 50% objective response rate.

Multicancer early detection: Can we screen for what we can't treat?

An FDA advisory panel has supported the clinical utility of multicancer early detection (MCED) tests, marking a potential shift in cancer screening paradigms.

Breast cancer home injections: Convenient for patients, complex for insurers

Despite the clinical benefits of home-based breast cancer therapy, insurance policies frequently impede patient access to these convenient injection programs.

Lung cancer in never smokers: The 60x risk factor you might be missing

A specific EGFR variant significantly increases lung cancer risk in individuals who have never smoked, challenging traditional views on lung cancer etiology. This genetic predisposition highlights a critical, often overlooked, pathway to disease development.

PPIs and cancer: Is CYP2C19 a friend or foe?

Genetic ancestry influences colorectal cancer risk through proton pump inhibitor metabolism, with CYP2C19 showing opposing roles in carcinogenesis versus precancerous states.